Piper Sandler analyst David Amsellem last night initiated coverage of Esperion (ESPR) with an Overweight rating and $9 price target The company’s bempedoic acid franchise for hypercholesterolemia and the reduction in associated cardiovascular disease risks positions it well for continued “rapid” volume and sales expansion, the analyst tells investors in a research note. Piper says its confidence is based on a “wide label,” which includes primary prevention, evolving clinical practice guidelines, and wide payer access.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESPR:
- Esperion initiated with an Overweight at Piper Sandler
- Esperion partner Otsuka launches NEXLETOL in Japan
- Esperion’s Global Expansion and Strategic Advancements Drive Buy Rating
- Esperion says HLS received approval from Health Canada to market NILEMDO
- Esperion’s Market Challenges: Sell Rating Due to Limited Impact of Bempedoic Acid and Mixed Feedback on Combination Strategy